Corsera Health
Corsera Health Raises $80M Series A | Once-Yearly Cardiovascular RNAi
Corsera Health Closes $80M Series A
Corsera Health, developing once-yearly RNAi treatments for cardiovascular diseases, has raised $80 million in Series A funding.
Key Highlights
- Novel once-yearly dosing approach
- Focus on cardiovascular diseases
- RNAi therapeutic platform
Company Overview
Corsera Health is developing RNA interference therapeutics that require only once-yearly dosing, potentially transforming treatment adherence for chronic cardiovascular conditions.
Company Info
Investors (2)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started


